Lung fluid immunoglobulin from HIV-infected subjects has impaired opsonic function against pneumococci

Roger Eagan; Homer L. Twigg; Neil French; Janelisa Musaya; Richard B. Day; Eduard E. Zijlstra; Helen Tolmie; David Wyler; Malcolm E. Molyneux; Stephen Gordon

doi:10.1086/518133

Lung fluid immunoglobulin from HIV-infected subjects has impaired opsonic function against pneumococci

Roger Eagan, Homer L. Twigg, Neil French, Janelisa Musaya, Richard B. Day, Eduard E. Zijlstra, Helen Tolmie, David Wyler, Malcolm E. Molyneux, Stephen Gordon

Clinical Sciences

Research output: Contribution to journal › Article › peer-review

29 Citations (Scopus)

Abstract

Background. The incidence of pneumococcal pneumonia is greatly increased among human immunodeficiency virus (HIV)-infected subjects, compared with among non-HIV-infected subjects. Lung fluid levels of immunoglobulin G (IgG) specific for pneumococcal capsular polysaccharide are not reduced in HIV-infected subjects; therefore, we examined immunoglobulin subtypes and compared lung fluid IgG opsonic function in HIV-infected subjects with that in healthy subjects.

Methods. Bronchoalveolar lavage (BAL) fluid and serum samples were collected from 23 HIV-infected and 26 uninfected subjects. None of the subjects were receiving highly active antiretroviral therapy, and none had received pneumococcal vaccination. Pneumococcal capsule-specific IgG levels in serum and BAL fluid were measured by enzyme-linked immunosorbent assay, and IgG was concentrated from 40 mL of BAL fluid. Opsonization and opsonophagocytosis of pneumococci with serum, BAL fluid, and BAL IgG were compared between HIV-infected subjects and healthy subjects.

Results. The effect of type 1 pneumococcal capsular polysaccharide - specific IgG in opsonizing of pneumococci was significantly less using both serum and BAL IgG from HIV-infected subjects, compared with serum and BAL IgG from healthy subjects (mean level, 8.9 fluorescence units [95% confidence interval, 8.1-9.7 fluorescence units] vs. 12.1 fluorescence units [95% confidence interval, 9.7-15.2 fluorescence units]; P = .002 for lung BAL IgG). The opsonophagocytosis of pneumococci observed using BAL IgG from HIV-infected subjects was significantly less than that observed using BAL IgG from healthy subjects (37 fluorescence units per ng of IgG [95% confidence interval, 25-53 fluorescence units per ng of IgG] vs. 127 fluorescence units per ng of IgG [95% confidence interval, 109-145 fluorescence units per ng of IgG]; P < .001).

Conclusion. HIV infection is associated with decreased antipneumococcal opsonic function in BAL fluid and serum.

Original language	English
Pages (from-to)	1632-1638
Number of pages	7
Journal	Clinical Infectious Diseases
Volume	44
Issue number	12
DOIs	https://doi.org/10.1086/518133
Publication status	Published - 15 Jun 2007

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1086/518133

Cite this

@article{13557f5890194ac59c0fdaa8d89fa3fc,

title = "Lung fluid immunoglobulin from HIV-infected subjects has impaired opsonic function against pneumococci",

abstract = "Background. The incidence of pneumococcal pneumonia is greatly increased among human immunodeficiency virus (HIV)-infected subjects, compared with among non-HIV-infected subjects. Lung fluid levels of immunoglobulin G (IgG) specific for pneumococcal capsular polysaccharide are not reduced in HIV-infected subjects; therefore, we examined immunoglobulin subtypes and compared lung fluid IgG opsonic function in HIV-infected subjects with that in healthy subjects.Methods. Bronchoalveolar lavage (BAL) fluid and serum samples were collected from 23 HIV-infected and 26 uninfected subjects. None of the subjects were receiving highly active antiretroviral therapy, and none had received pneumococcal vaccination. Pneumococcal capsule-specific IgG levels in serum and BAL fluid were measured by enzyme-linked immunosorbent assay, and IgG was concentrated from 40 mL of BAL fluid. Opsonization and opsonophagocytosis of pneumococci with serum, BAL fluid, and BAL IgG were compared between HIV-infected subjects and healthy subjects.Results. The effect of type 1 pneumococcal capsular polysaccharide - specific IgG in opsonizing of pneumococci was significantly less using both serum and BAL IgG from HIV-infected subjects, compared with serum and BAL IgG from healthy subjects (mean level, 8.9 fluorescence units [95\% confidence interval, 8.1-9.7 fluorescence units] vs. 12.1 fluorescence units [95\% confidence interval, 9.7-15.2 fluorescence units]; P = .002 for lung BAL IgG). The opsonophagocytosis of pneumococci observed using BAL IgG from HIV-infected subjects was significantly less than that observed using BAL IgG from healthy subjects (37 fluorescence units per ng of IgG [95\% confidence interval, 25-53 fluorescence units per ng of IgG] vs. 127 fluorescence units per ng of IgG [95\% confidence interval, 109-145 fluorescence units per ng of IgG]; P < .001).Conclusion. HIV infection is associated with decreased antipneumococcal opsonic function in BAL fluid and serum.",

author = "Roger Eagan and Twigg, \{Homer L.\} and Neil French and Janelisa Musaya and Day, \{Richard B.\} and Zijlstra, \{Eduard E.\} and Helen Tolmie and David Wyler and Molyneux, \{Malcolm E.\} and Stephen Gordon",

year = "2007",

month = jun,

day = "15",

doi = "10.1086/518133",

language = "English",

volume = "44",

pages = "1632--1638",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "12",

}

TY - JOUR

T1 - Lung fluid immunoglobulin from HIV-infected subjects has impaired opsonic function against pneumococci

AU - Eagan, Roger

AU - Twigg, Homer L.

AU - French, Neil

AU - Musaya, Janelisa

AU - Day, Richard B.

AU - Zijlstra, Eduard E.

AU - Tolmie, Helen

AU - Wyler, David

AU - Molyneux, Malcolm E.

AU - Gordon, Stephen

PY - 2007/6/15

Y1 - 2007/6/15

N2 - Background. The incidence of pneumococcal pneumonia is greatly increased among human immunodeficiency virus (HIV)-infected subjects, compared with among non-HIV-infected subjects. Lung fluid levels of immunoglobulin G (IgG) specific for pneumococcal capsular polysaccharide are not reduced in HIV-infected subjects; therefore, we examined immunoglobulin subtypes and compared lung fluid IgG opsonic function in HIV-infected subjects with that in healthy subjects.Methods. Bronchoalveolar lavage (BAL) fluid and serum samples were collected from 23 HIV-infected and 26 uninfected subjects. None of the subjects were receiving highly active antiretroviral therapy, and none had received pneumococcal vaccination. Pneumococcal capsule-specific IgG levels in serum and BAL fluid were measured by enzyme-linked immunosorbent assay, and IgG was concentrated from 40 mL of BAL fluid. Opsonization and opsonophagocytosis of pneumococci with serum, BAL fluid, and BAL IgG were compared between HIV-infected subjects and healthy subjects.Results. The effect of type 1 pneumococcal capsular polysaccharide - specific IgG in opsonizing of pneumococci was significantly less using both serum and BAL IgG from HIV-infected subjects, compared with serum and BAL IgG from healthy subjects (mean level, 8.9 fluorescence units [95% confidence interval, 8.1-9.7 fluorescence units] vs. 12.1 fluorescence units [95% confidence interval, 9.7-15.2 fluorescence units]; P = .002 for lung BAL IgG). The opsonophagocytosis of pneumococci observed using BAL IgG from HIV-infected subjects was significantly less than that observed using BAL IgG from healthy subjects (37 fluorescence units per ng of IgG [95% confidence interval, 25-53 fluorescence units per ng of IgG] vs. 127 fluorescence units per ng of IgG [95% confidence interval, 109-145 fluorescence units per ng of IgG]; P < .001).Conclusion. HIV infection is associated with decreased antipneumococcal opsonic function in BAL fluid and serum.

AB - Background. The incidence of pneumococcal pneumonia is greatly increased among human immunodeficiency virus (HIV)-infected subjects, compared with among non-HIV-infected subjects. Lung fluid levels of immunoglobulin G (IgG) specific for pneumococcal capsular polysaccharide are not reduced in HIV-infected subjects; therefore, we examined immunoglobulin subtypes and compared lung fluid IgG opsonic function in HIV-infected subjects with that in healthy subjects.Methods. Bronchoalveolar lavage (BAL) fluid and serum samples were collected from 23 HIV-infected and 26 uninfected subjects. None of the subjects were receiving highly active antiretroviral therapy, and none had received pneumococcal vaccination. Pneumococcal capsule-specific IgG levels in serum and BAL fluid were measured by enzyme-linked immunosorbent assay, and IgG was concentrated from 40 mL of BAL fluid. Opsonization and opsonophagocytosis of pneumococci with serum, BAL fluid, and BAL IgG were compared between HIV-infected subjects and healthy subjects.Results. The effect of type 1 pneumococcal capsular polysaccharide - specific IgG in opsonizing of pneumococci was significantly less using both serum and BAL IgG from HIV-infected subjects, compared with serum and BAL IgG from healthy subjects (mean level, 8.9 fluorescence units [95% confidence interval, 8.1-9.7 fluorescence units] vs. 12.1 fluorescence units [95% confidence interval, 9.7-15.2 fluorescence units]; P = .002 for lung BAL IgG). The opsonophagocytosis of pneumococci observed using BAL IgG from HIV-infected subjects was significantly less than that observed using BAL IgG from healthy subjects (37 fluorescence units per ng of IgG [95% confidence interval, 25-53 fluorescence units per ng of IgG] vs. 127 fluorescence units per ng of IgG [95% confidence interval, 109-145 fluorescence units per ng of IgG]; P < .001).Conclusion. HIV infection is associated with decreased antipneumococcal opsonic function in BAL fluid and serum.

U2 - 10.1086/518133

DO - 10.1086/518133

M3 - Article

SN - 1058-4838

VL - 44

SP - 1632

EP - 1638

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 12

ER -

Lung fluid immunoglobulin from HIV-infected subjects has impaired opsonic function against pneumococci

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this